Sun Pharma launches only approved sprinkle formulation cap
Sun Pharma launches only approved sprinkle formulation cap

Sun Pharma launches only approved sprinkle formulation cap

DSIJ Intelligence Article rating: 3.0

Sun Pharma launched Ezallor Sprinkle (rosuvastatin) capsules in the US market to treat three kinds of elevated lipid disorders for people who have difficulty in swallowing. It is the first and only FDA-approved sprinkle formulation of rosuvastatin capsules.

Fire accident at Punjab Chemicals' agro plant
Fire accident at Punjab Chemicals' agro plant

Fire accident at Punjab Chemicals' agro plant

DSIJ Intelligence Article rating: 3.8

Punjab Chemicals and Crop Protection reported the exchanges about a fire accident which occurred at one of the company’s agro division plant in Derabassi in Punjab.

Indigo experiences turbulence due to promoter feud
Indigo experiences turbulence due to promoter feud

Indigo experiences turbulence due to promoter feud

DSIJ Intelligence Article rating: 5.0

The operator of IndiGo Airlines, Interglobe Aviation’s co-founder raised corporate governance issue in the company with the Securities and Exchange Board of India (SEBI). Reacting to this development, the stock crashed by 10.73 per cent on Wednesday.

Glenmark Pharma gets ANDA approval for Ranolazine
Glenmark Pharma gets ANDA approval for Ranolazine

Glenmark Pharma gets ANDA approval for Ranolazine

DSIJ Intelligence Article rating: 5.0

Glenmark Pharmaceuticals Inc. has received final approval from United States Food & Drug Administration (USFDA) for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg.

Overnight Digest: Stocks to look out for on July 9
Overnight Digest: Stocks to look out for on July 9

Overnight Digest: Stocks to look out for on July 9

DSIJ Intelligence Article rating: 5.0

As the Sensex fell by 793 points and Nifty settled below the 11,600 level, the stocks to watch out on July 9 include Voltas, BASF India, Eris Lifesciences, Reliance Industries, Mindtree and Punjab National Bank.

Biocon gets USFDA observations
Biocon gets USFDA observations

Biocon gets USFDA observations

DSIJ Intelligence Article rating: 5.0

Biocon has been issued 12 observations by the USFDA for its assembly facilities in Malaysia. Despite the news, the stock price of the company increased by 1.5 per cent.

RSS
First7374757678808182Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR